Inicure AB
559493-9430ActiveDeveloping novel small molecules to combat resistant bacterial infections effectively.
Oversigt
- 0
- Medarbejdere
- ≤1t SEK
- Omsætning
- 2024
- Grundlagt
Nøglebeslutningstagere
Peter Olofsson-Sahl
CEO
Johan Bylund
CSO
Sara Malcus
Chair Board of Directors
Felix Sanchez Klose
Researcher — Product Development
Beskrivelse
Inicure AB is a biotechnology company spun off from Pronoxis AB, established in 2024. The core mission of the organization is to combat the growing global threat of antibiotic resistance. They specialize in developing novel anti-infectious assets based on activating the formyl peptide receptor-1 (FP...
Tags
Nøgleord
Teknologistak
Virksomhedsoplysninger
- Branche
- Annan naturvetenskaplig och teknisk forskning och utveckling
- Juridisk form
- Aktiebolag
- Momsnummer
- SE559493943001
Beslutningstagere
4 kontakter i FunnelfeedrPeter Olofsson-Sahl
CEO
Johan Bylund
CSO
Sara Malcus
Chair Board of Directors
Andre kontakter
Felix Sanchez Klose
Researcher — Product Development
Lignende virksomheder
20 lignende virksomheder i FunnelfeedrQureTech Bio AB
5–9 medarbejdereDeveloping novel synthetic antibiotics to combat drug-resistant bacteria.
Ribocure Pharmaceuticals AB
20–49 medarbejdereClinical stage biotech developing cutting-edge RNA therapeutics for rare diseases.
Linnane Pharma AB
Developing novel drugs for cancer and infections via proprietary platform.
ProNoxis AB
1 medarbejdereDeveloping small molecule drugs targeting NOX2 activation for inflammation treatment.
SynAct Pharma AB
5–9 medarbejdereClinical-stage biotech resolving inflammation via novel oral therapies.
Udforsk mere
Spørgsmål om Inicure AB
Vil du se Funnelfeedr i aktion?
Book en gratis demo og opdag, hvordan Funnelfeedr hjælper dig med at finde og konvertere dine ideelle kunder.
Book en demo